A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma
Latest Information Update: 02 Nov 2021
At a glance
- Drugs LCAR L10D (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions; Pharmacodynamics
Most Recent Events
- 02 Nov 2021 Status changed from recruiting to discontinued.
- 04 Dec 2020 Planned number of patients changed from 9 to 28.
- 04 Dec 2020 Planned primary completion date changed from 1 May 2023 to 1 May 2021.